10/580417

MODIFIED PTO/SB/08 A & B (08-03)

Substitute for Form 1449 A & B/PTO

Shect

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2

10 S The Complete of Known 22 MAY 2006 Application Number Based on PCT/JP04/017521 Confirmation Number Unknown Filing Date May 22, 2006 First Named Inventor Miki KOBAYASHI Art Unit Unknown Examiner Name Unknown Attorney Docket Number Q94782

U.S. PATENT DOCUMENTS								
Examiner		Document Number		Publication Date				
Initials*	Cite No.1	Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			
/JK/		US 5,712,298	A	01-27-1998	Hermann Amschler			
1		US 6,740,662	Bi	05-25-2004	Masahiro Iwata, et al.			
		US 2004/0192701	Al	09-30-2004	Masahiro Iwata, et al.			
3/		US 5,817,670	A	10-06-1998	Kazuhisa Takayama, et al.			
The same of		US 6,136,810	A	10-24-2000	Kazuhisa Takayama, et al.			
/JK/		US 6,544,983	B2	04-08-2003	Annette Doherty			

County Number Kidd Code' MM-DD-YYYY Applicant of Cited Document MM-DD-YYYY MM-DD-YYYY Applicant of Cited Document MM-DD-YYYY MM-D	FOREIGN PATENT DOCUMENTS									
Code Number Road Code MM-DD-YYY Applicant of Cited Document	Examiner		Foreign Patent Document		Publication Date	Name of Patentee or				
WO 95/24381 A1 09-14-1995 SMITHKINE BEECHAM CORPORATION	Initials*	Cite No.		Number ⁴		MM-DD-YYYY	Applicant of Cited Document	Translation ⁶		
WO 95/24381 A1 09-14-1995 CORPORATION	/JK/		wo	99/57303	Al	11-11-1999				
WO 01/87281 A2 11-22-2001 SMITHKLINE BEECHAM P.L.C			wo	95/24381	Al	09-14-1995				
			wo	01/87281	A2	11-22-2001	SMITHKLINE BEECHAM P.L.C.			
JP 11-292878 A 10-26-1999 Yamanouchi Pharm. Co. Ltd. Abst	Ψ		JP	11-292878	Α	10-26-1999	Yamanouchi Pharm. Co. Ltd.	Abstract		
/JK/ JP 11-292877 A 10-26-1999 Yamanouchi Pharm. Co. Ltd. Abst	/JK/		JP	11-292877	Α	10-26-1999	Yamanouchi Pharm. Co. Ltd.	Abstract		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initiais* Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.					
		ARMIN HATZELMANN, et al., "Anti-Inflammatory and immunomodulatory Potential of the Novel PDE4					
/JK/		Inhibitor Roflumilast in Vitro", The Journal of Pharmacology and Experimental Therapeutics, 2001, pp. 267-					
		279, Vol. 297, No. 1					
3		"Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on					
1		Interstitial Cystitis, National Institutes of Health, Bethesda Maryland", The Journal of Urology, August 28-29,					
1	l	1987, pp. 203-206, Vol. 140					
		S. LARSEN, et al., "Mast Cells in Interstitial Cystitis", British Journal of Urology, 1982, pp. 283-286, Vol. 54					
		J. KASTRUP, et al., "Histamine Content and Mast Cell Count of Detrusor Muscle in Patients with Interstitial					
1		Cystitis and Other Types of Chronic Cystitis", British Journal of Urology, 1983, pp. 495-500, Vol. 55					
		TETSUO YAMADA, et al., "Alternate occurrence of Allergic Disease and an Unusual Form of Interstitial					
1		Cystitis", Int. J. Urol. 1998, pp. 329-336, Vol. 5					
		DEBORAH R. ERICKSON, et al., "Inflammatory Cell types and Clinical Features of Interstitial Cystitis", The					
, l		Journal of Urology, 1997, pp. 790-793, Vol. 158					
W.		DEBORAH R. ERICKSON, "Urine Markers of Interstitial Cystitis", Urology, 2001, pp. 15-21, Vol. 57					
1 (H. RICHARD HELLSTROM, et al., "Eosinophilic Cystitis", A.J.C.P., November 1979, pp. 777-784, Vol. 72,					
/JK/	1	No. 5					

Examiner Signature	/Jennifer Kim/	Date Considered	9/26/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 991.04 or follow the hyperlink from the title of the documents to the imment. *Enter Office that issued the document, by the two-lenter code (WIPO Standard ST. 3). *For Juquesce patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to indicate here if English language Translation is mathered.**

10/580417

1AP9 Rec'd PCT/PTO 22 MAY 2006 Complete if Known Substitute for Form 1449 A & B/PTO Application Number Based on PCT/JP04/017521 Confirmation Number Unknown INFORMATION DISCLOSURE May 22, 2006 Filing Date STATEMENT BY APPLICANT First Named Inventor Miki KOBAYASHI (use as many sheets as necessary) Art Unit Unknown Examiner Name Unknown

Sheet		2	of 2	Atto	rney Docket Number	Q94782		
				J.S. PATENT DOCU	MENIS			
Examiner	Cite No.1	Document N	umber	Publication Date	Name of Patentee or Applicant of Cited Document			
Initials*		Number	Kind Co	de' MM-DD-VVVV				
		US						

FOREIGN PATENT DOCUMENTS									
Examiner County Foreign Patent Document Publication Date Name of Patentee or									
Initials*	Cite No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation*		

Examiner		NON PATENT LITERATURE DOCUMENTS	
Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation
/JK/		JAMES A. KOZIOL, et al., "The Natural History of Interstitial Cystitis; A Survey of 374 Patients", The Journal of Urology, March 1993, pp. 465-469, Vol. 149	
		MADHU ALAGIRI, et al., "Interstitial Cystitis: Unexplained Associations with Other Chronic Disease and Pain Syndromes", 1997, pp. 52-57, Vol. 49	
		ERIC ROVNER, et al., "Treatments used in Women with Interstitial Cystitis: The Interstitial Cystitis Data Base (ICDB) Study Experience", Adult Urology, 2000, pp. 940-945, Vol. 56, No. 6	
		THEOHARIS C. THEOHARIDES, et al., "New agents for the medical treatment of interstitial cystitis", Exp. Opin. Invest. Drugs, 2001, pp. 521-546	
		"NIH Consensus Definition and Classification of Prostatitis", JAMA, July 21, 1999, pp. 236-237, Vol. 281, No. 3	
		IRFAN ORHAN, et al., "Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome", International Journal of Urology, 2001, Vol. 8, pp. 495-499	
		RICHARD B. ALEXANDER, et al., "Autoimmune Prostatitis: Evidence of T Cell Reactivity with Normal Prostatic Proteins", Adult Urology, 1997, pp. 893-899, Vol. 50, No. 6	
		JANE L. MILLER, et al., "Prostatodynia and Interstitial Cystitis: one and the same?", Adult Urology, April 1995, pp. 587-590, Vol. 45, No. 4	
		THEODORE J. TORPHY, "Phosphodiesterase Isozymes", Am. J. Respir. Crit. Care Med., 1998, pp. 351-370, Vol. 157	
		SCOTT H. SODERLING, et al., "Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions", Curr. Opin. Cell Biol., 2000, pp. 174-179	
		DAVID M. ESSAYAN, "Molecular mechanisms in allergy and clinical immunology", J. Allergy Clin. Immunol., November 2001, pp. 671-680	
		MAURO M. TEIXEIRA, et al., "Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?", TiPS, May 1997, pp. 164-170, Vol. 18	
		JOHN E. SOUNESS, et al., "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors", Immunopharmacology, 2000, pp. 127-162, Vol. 47	
V		DAVID C. UNDERWOOD, et al., "Antiasthmatic Activity of the Second-Generation Phosphodiesterase 4 (PDE4) Inhibitor SB 207499 (Ariflo) in the Guinea Pig", The Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 988-995, Vol. 287, No. 3	
/JK/		International Search Report for PCT/JP04/017521 dated December 28, 2004	

Examiner Signature	/Jennifer Kim/	Date Considered	9/26/2008
		<u>-</u>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation combet (optional). See Kind Codes of USFTO Parent Documents at www.uspia.gov, MPEP 901.04 or follow the hyperlink from the table of the documents to the internet. Fair Office the internet. See a feed of the companies of the particle. Applicant is a feed of the particle with a particle of the particle with a feed of the particle